Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Overactive Bladder - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape. Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 4, 4, 2, 10 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Overactive Bladder. Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Overactive Bladder Overview 10 Therapeutics Development 11 Pipeline Products for Overactive Bladder - Overview 11 Pipeline Products for Overactive Bladder - Comparative Analysis 12 Overactive Bladder - Therapeutics under Development by Companies 13 Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 15 Overactive Bladder - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Overactive Bladder - Products under Development by Companies 19 Overactive Bladder - Products under Investigation by Universities/Institutes 21 Overactive Bladder - Companies Involved in Therapeutics Development 22 Addex Therapeutics Ltd 22 Allergan Plc 23 Asahi Kasei Pharma Corp. 24 Astellas Pharma Inc. 25 Dompe Farmaceutici S.p.A. 26 Dong-A Socio Holdings Co. Ltd. 27 FemmePharma Global Healthcare, Inc. 28 Hanmi Pharmaceuticals, Co. Ltd. 29 Hydra Biosciences, Inc. 30 Ion Channel Innovations, LLC 31 Ipsen S.A. 32 Jeil Pharmaceutical Co., Ltd. 33 Juniper Pharmaceuticals, Inc. 34 Lipella Pharmaceuticals, Inc. 35 Merck & Co., Inc. 36 Mezzion Pharma Co. Ltd. 37 Ono Pharmaceutical Co., Ltd. 38 Recordati S.p.A. 39 Sanofi 40 Seoul Pharma Co., Ltd. 41 Taris Biomedical LLC 42 TheraVida, Inc. 43 Toray Industries, Inc. 44 UroGen Pharmaceuticals, Ltd. 45 XuanZhu Pharma Co., Ltd. 46 Overactive Bladder - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 (mirabegron + solifenacin succinate) - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 abobotulinumtoxin A - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 ADX-71441 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 DA-8010 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 DFL-23448 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 fadanafil - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 HC-067047 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 HIP-1503 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 mirabegron ER - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 onabotulinumtoxin A - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 onabotulinumtoxinA - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 onabotulinumtoxinA SR - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 ONO-8577 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 oxybutynin chloride - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 oxybutynin chloride - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 pVAX-hSlo - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 REC-0438 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 SAR-244181 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 solabegron hydrochloride - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 solifenacin succinate - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 SPO-1406 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 tacrolimus - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 TAR-302 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 THVD-201 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 udenafil - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 vibegron - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Overactive Bladder - Dormant Projects 105 Overactive Bladder - Discontinued Products 111 Overactive Bladder - Product Development Milestones 113 Featured News & Press Releases 113 Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver 113 May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego 113 Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women 114 Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product 115 Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting 115 Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder 116 May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 116 May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 118 Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 118 Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 118 Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 119 Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK 120 Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 121 May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 121 May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder 122 Appendix 123 Methodology 123 Coverage 123 Secondary Research 123 Primary Research 123 Expert Panel Validation 123 Contact Us 123 Disclaimer 124
List of Tables
Number of Products under Development for Overactive Bladder, H2 2016 11 Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2016 22 Overactive Bladder - Pipeline by Allergan Plc, H2 2016 23 Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2016 24 Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2016 25 Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 26 Overactive Bladder - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 27 Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016 28 Overactive Bladder - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 29 Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2016 30 Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2016 31 Overactive Bladder - Pipeline by Ipsen S.A., H2 2016 32 Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 33 Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016 34 Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016 35 Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2016 36 Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 37 Overactive Bladder - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 38 Overactive Bladder - Pipeline by Recordati S.p.A., H2 2016 39 Overactive Bladder - Pipeline by Sanofi, H2 2016 40 Overactive Bladder - Pipeline by Seoul Pharma Co., Ltd., H2 2016 41 Overactive Bladder - Pipeline by Taris Biomedical LLC, H2 2016 42 Overactive Bladder - Pipeline by TheraVida, Inc., H2 2016 43 Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2016 44 Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 45 Overactive Bladder - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 46 Assessment by Monotherapy Products, H2 2016 47 Assessment by Combination Products, H2 2016 48 Number of Products by Stage and Target, H2 2016 50 Number of Products by Stage and Mechanism of Action, H2 2016 52 Number of Products by Stage and Route of Administration, H2 2016 54 Number of Products by Stage and Molecule Type, H2 2016 56 Overactive Bladder - Dormant Projects, H2 2016 105 Overactive Bladder - Dormant Projects (Contd..1), H2 2016 106 Overactive Bladder - Dormant Projects (Contd..2), H2 2016 107 Overactive Bladder - Dormant Projects (Contd..3), H2 2016 108 Overactive Bladder - Dormant Projects (Contd..4), H2 2016 109 Overactive Bladder - Dormant Projects (Contd..5), H2 2016 110 Overactive Bladder - Discontinued Products, H2 2016 111 Overactive Bladder - Discontinued Products (Contd..1), H2 2016 112
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
